Durvalumab for Early-stage non-small cell lung cancer

Inclusion criteria

• {"criterion_text":"- Histologically confirmed NSCLC\n- T1c-3N0-2, here T3 tumors are based on size, but not based in invasion into the thoracic wall, mediastinum, vertebra or diaphragm or ipsilateral lung nodules\n- Willing and able to provide written informed consent for the trial\n- Above 18 years of age on day of signing informed consent\n- Have measurable disease based on RECIST 1.1\n- Have a ECOG performance status of 0-1, and are considered operable based on pulmonary function test and/or exercise testing\n- Demonstrate adequate organ function, as deemed acceptable by the treating physician in the context of immunotherapy: a. Leukocytes ≥ 3,000/mm3 b. Absolute neutrophil count (ANC) ≥ 1000/mm3 c. Platelet count ≥ 75,000/mm3 d. Hemoglobin ≥ 6 mmol/L (9.7 g/dL) e. Creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥40 mL/min (if using the Cockcroft-Gault formula below): i. Female CrCl = [(140 - age) x weight x 0.85]/(0.85 x creat in mmol/L) ii. Male CrCl = [(140 - age) x weight x 1.00]/(0.81 x creat in mmol/L) f. Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome) g. AST and ALT ≤ 2.5 times the upper limit of normal h. Subjects must have adequate lung function to permit surgical resection determined by preenrollment pulmonary function tests to include DLCO\n- Body weight >30 kg\n- Must have a life expectancy of at least 12 weeks"}

Exclusion criteria

• {"criterion_text":"- Prior surgery and/or radiotherapy on the ipsilateral thorax\n- Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n- Has received prior therapy with an anti-PD-1, anti-PD-L1 including durvalumab, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.\n- Patient is pregnant or breastfeeding or expecting to conceive within the projected duration of the trial, starting with the pre-screening or screening visit through 23 weeks after the last dose of trial treatment.\n- Patients deemed inoperable\n- Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of day 0. Inhaled or topical steroids, and adrenal replacement steroid >10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.\n- Additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.\n- Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this criterion:  Patients with vitiligo or alopecia  Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement  Any chronic skin condition that does not require systemic therapy  Patients without active disease in the last 5 years may be included but only after consultation with the study physician  Patients with celiac disease controlled by diet alone\n- Uncontrolled intercurrent illness, including but not limited to symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent\n- Active infection requiring systemic therapy.\n- A history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).\n- Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA."}

Primary endpoints

• {"endpoint_text":"- Safety defined as the percentage of patients with adverse events.","definition_or_measurement_approach":"Safety measured as the percentage of patients with adverse events."}
• {"endpoint_text":"- Major pathological response (MPR) and pathological complete response (pCR) rates in resected tumor-specimens.","definition_or_measurement_approach":"Pathological response rates (MPR and pCR) assessed in resected tumor specimens."}

Secondary endpoints

• {"endpoint_text":"- Tumor immune infiltration after durvalumab and RT in 4 categories.","definition_or_measurement_approach":"Tumor immune infiltration categorized into four categories after treatment with durvalumab and radiotherapy."}
• {"endpoint_text":"- Radiological response to durvalumab and RT using RECIST v1.1 criteria, and metabolic response based on 18F-FDG PET.","definition_or_measurement_approach":"Radiological response assessed by RECIST v1.1; metabolic response assessed by 18F-FDG PET."}

Netherlands

Earliest CTIS Part Ii Submission Date

25-10-2024

Latest Decision Or Authorization Date

29-10-2024

Processing Time Days

4

Number Of Sites

3

Number Of Participants

12

Primary sponsor

Full Name

Stichting Amsterdam UMC

Organisation Type

Hospital/Clinic/Other health care facility

Country Of Registered Address

Netherlands